- Home
- MX vs NGEN Comparison
MX vs NGEN Comparison
Compare MX & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MX | NGEN |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | South Korea | Canada |
| Employees | N/A | 9 |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.2M | 175.1M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | MX | NGEN |
|---|---|---|
| Price | $8.86 | $2.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.75 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 2.5M | 1.0M |
| Earning Date | 04-28-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $178,860,000.00 | N/A |
| Revenue This Year | $8.55 | N/A |
| Revenue Next Year | $6.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.18 | $1.98 |
| 52 Week High | $7.05 | $5.93 |
Technical Indicators
Market Signals| Indicator | MX | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 78.89 | 22.47 |
| Support Level | $2.66 | N/A |
| Resistance Level | N/A | $4.52 |
| Average True Range (ATR) | 0.77 | 0.17 |
| MACD | 0.36 | -0.18 |
| Stochastic Oscillator | 85.61 | 4.21 |
Price Performance
Historical ComparisonAbout MX Magnachip Semiconductor Corporation
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The Company operates within a single operating segment, Power Solutions business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.